Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China's Drug Regulators Issue Warning On Use Of Avandia While Debating Suspension Vs. Restricted Use

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - China's State FDA issued a warning Sept. 25 on the potential cardiovascular risk of using drugs containing rosiglitazone and told the public that the agency is organizing a committee of experts to evaluate the benefits and risks of rosiglitazone drugs, including GlaxoSmithKline's Avandia (rosiglitazone), Avandamet (metformin and rosiglitazone) and generics

You may also be interested in...



As More Leading Doctors Oppose Avandia, Will Indian Regulators Propose A Ban?

MUMBAI - Leading Indian doctors have begun speaking out against GlaxoSmithKline's anti-diabetes brand Avandia (rosiglitazone) - branded as Windia in the Indian market - after U.S.FDA restricted the drug's use and European regulatory authorities ordered a complete withdrawal of the medicine from the market

Like U.S. Counterparts, South Korea FDA Regulators Move To Severely Restrict Use Of Diabetes Treatments Including GSK's Avandia

SEOUL - Following a U.S. FDA action to drastically limit the use of diabetes treatments containing rosiglitazone, Korea FDA is adopting similar measures, advising doctors and patients not to use 15 of these medicines available locally including GlaxoSmithKline's Avandia

GSK Will End Avandia Promotion Worldwide

Even in countries where the drug will still be sold, the firm projects "minimal" sales.

Related Content

UsernamePublicRestriction

Register

SC076025

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel